公开(公告)号：US20240382411A1

公开(公告)日：2024-11-21

申请号：US18691672

申请日：2022-09-16

Applicant: JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD ,  SUZHOU ALPHAMAB CO., LTD.

Inventor： Ting Xu ,  Kangping Guo ,  Lihong Yun ,  Yuanli Wu ,  Yan Huang ,  Hongqin Hu

IPC: A61K9/00 ,  A61K9/08 ,  A61K39/00 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  C07K16/28

Abstract: The present application relates to a composition comprising an antigen-binding fragment and an excipient. The antigen-binding fragment comprises an immunoglobulin single variable domain capable of specifically binding to PD-L1 and comprising CDR1-3, the CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 47, and the excipient may comprise proline. The composition has good stability and suitable viscosity and can be used for subcutaneous injection.

公开(公告)号：US20240076345A1

公开(公告)日：2024-03-07

申请号：US18270097

申请日：2021-12-27

Applicant: SUZHOU ALPHAMAB CO., LTD

Inventor： Ting XU ,  Yuhao JIN ,  Xiaoxiao WANG ,  Pilin WANG ,  Qian LI

IPC: C07K14/605 ,  A61K38/26 ,  A61P3/10

CPC classification number: C07K14/605 ,  A61K38/26 ,  A61P3/10 ,  C07K2319/30

Abstract: A human GLP-1 polypeptide variant, and a fusion protein or an immunoconjugate constructed by means of using the human GLP-1 polypeptide variant can be used for preventing, and/or treating metabolic diseases or conditions related to GLP-1.

公开(公告)号：US11377497B2

公开(公告)日：2022-07-05

申请号：US16479858

申请日：2018-01-23

Applicant: SUZHOU ALPHAMAB CO., LTD.

Inventor： Ting Xu ,  Aiwu Zhou ,  Yuhao Jin ,  Ling Wang ,  Jie Wu ,  Hongqin Hu ,  Xiaoxiao Wang

IPC: C07K16/28 ,  C12N15/85 ,  A61K39/395 ,  G01N33/577 ,  G01N33/68

Abstract: The present invention relates to the field of medical biology, and discloses a high-resolution crystal structure of a complex of PD-L1-blocking heavy-chain single-domain antibody KN035 binding with PD-L1, and the use of the crystal structure. The invention also relates to novel PD-L1 binding polypeptides or compounds developed based on the crystal structure and uses thereof.

公开(公告)号：US20250034277A1

公开(公告)日：2025-01-30

申请号：US18714678

申请日：2022-11-29

Applicant: SUZHOU ALPHAMAB CO., LTD.

Inventor： Ting XU ,  Qun YIN ,  Rongmei YAN ,  Qian LI ,  Yan WANG

IPC: C07K16/36 ,  A61K39/00 ,  A61P7/02

Abstract: The present invention relates to a method for preventing and/or treating thromboembolic diseases, comprising the following step: administering a coagulation factor XI (FXI) binding protein to a subject in need thereof, which binding protein can comprise at least one immunoglobulin single variable domain capable of specifically binding to FXI, wherein the at least one immunoglobulin single variable domain may comprise CDR1, CDR2, and CDR3 in a VHH as shown in any one of SEQ ID NOs: 4, 10, and 14.

公开(公告)号：US20190031782A1

公开(公告)日：2019-01-31

申请号：US15541921

申请日：2016-01-08

Applicant: SUZHOU ALPHAMAB CO., LTD

Inventor： Ting XU ,  Tau XU ,  Xiaoxiao WANG ,  Qian LI ,  Minjie PANG ,  Huimin ZHANG ,  Li HAN ,  Li HAN

IPC: C07K16/46 ,  C07K16/32 ,  A61P35/00

Abstract: The present application provides a bispecific antibody or an antibody mixture with common light chains and a preparation method therefor. the present application also provides a nucleic acid molecule encoding the antibody or the mixture, a recombinant vector and a recombinant cell comprising the nucleic acid molecule, as well as a detection and quantitation method for the antibody or the mixture.

公开(公告)号：US09969786B2

公开(公告)日：2018-05-15

申请号：US14646926

申请日：2013-11-22

Applicant: SUZHOU ALPHAMAB CO., LTD.

Inventor： Ting Xu ,  Kangping Guo ,  Lihong Yun

IPC: C07K14/59 ,  A61K38/24 ,  A61K38/00

CPC classification number: C07K14/59 ,  A61K38/00 ,  A61K38/24 ,  C07K2319/30

Abstract: Disclosed herein is a gonadotropin fusion protein or a thyroid stimulating hormone fusion protein, a method for preparing the same and use thereof. β-subunit of the gonadotropin or thyroid stimulating hormone is fused to an Fc fragment directly or indirectly through a linker, and α-subunit binds to the β-subunit via an affinity between the α-subunit and the β-subunit. The fusion protein has a prolonged half-life and less fluctuating activity.

公开(公告)号：US20220017643A1

公开(公告)日：2022-01-20

申请号：US17496240

申请日：2021-10-07

Applicant: JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD. ,  SUZHOU ALPHAMAB CO., LTD.

Inventor： Ting XU

IPC: C07K16/46 ,  C12P21/00 ,  C12N15/11 ,  A61K39/395 ,  C07K16/00 ,  C07K19/00 ,  C12N15/62

Abstract: The disclosure is directed to a heterodimer molecule, comprising a first polypeptide chain and a second polypeptide chain, and the first polypeptide chain comprises a first CH3 domain of an antibody heavy chain constant region, the second polypeptide chain comprises a second CH3 domain of an antibody heavy chain constant region. Comparing to a corresponding wild-type CH3 domain of a human antibody heavy chain constant region, the first CH3 domain and the second CH3 domain comprise amino acid mutations at specific positions, for example T366+K409+K392 and T366+L368+Y407+D399+F405, respectively.

公开(公告)号：US11225522B2

公开(公告)日：2022-01-18

申请号：US15748421

申请日：2016-08-01

Applicant: Suzhou Alphamab Co., LTD.

Inventor： Ting Xu ,  Yanrong Dong ,  Pilin Wang ,  Ting Chen

IPC: C07K16/28 ,  A61K39/395 ,  C12N5/10 ,  C12N15/85 ,  A61P35/00 ,  A61K45/06 ,  C07K16/30 ,  A61K47/68 ,  G01N33/574 ,  A61K39/00 ,  A61N5/10

Abstract: The present invention relates to the field of medical biology and discloses a single domain antibody and derivative proteins thereof against programmed death ligand (PDL1). In particular, the present invention discloses a programmed death ligand 1 (PDL1) binding molecule and the use thereof, especially the use for treating and/or preventing or diagnosing PDL1 relevant diseases such as tumor.

公开(公告)号：US20190315864A1

公开(公告)日：2019-10-17

申请号：US16302583

申请日：2017-05-19

Applicant: SUZHOU ALPHAMAB CO., LTD. ,  XITIAN ZHANG ,  XIN ZHANG

Inventor： Ting Xu ,  Xiaoxiao Wang ,  Jie Li ,  Haiyan Wu ,  Li Gao ,  Qian Chu ,  Yu Bai

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/22 ,  C07K16/32 ,  A61P35/00 ,  C12N15/70

Abstract: The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against CTLA4. In particular, the present invention discloses a CTLA4 binding protein and the use thereof, especially the use for treating and/or preventing CTLA4 relevant diseases such as tumor.

公开(公告)号：US20190055295A1

公开(公告)日：2019-02-21

申请号：US15978857

申请日：2018-05-14

Applicant: SUZHOU ALPHAMAB CO., LTD

Inventor： Ting XU ,  Kangping GUO ,  Lihong YUN

IPC: C07K14/59 ,  A61K38/24

Abstract: Disclosed herein is a gonadotropin fusion protein or a thyroid stimulating hormone fusion protein, a method for preparing the same and use thereof. β-subunit of the gonadotropin or thyroid stimulating hormone is fused to an Fc fragment directly or indirectly through a linker, and α-subunit binds to the β-subunit via an affinity between the α-subunit and the β-subunit. The fusion protein has a prolonged half-life and less fluctuating activity.